BuChE/FAAH-IN-1

BuChE/FAAH-IN-1 (2.5-10 μM; pretreatment for 1 h + co-culture for 24 h) dose-dependently promotes M2 polarization and inhibits M1 markers in LPS-stimulated BV2 microglia (upregulates Arg-1 and CD206, downregulates IL-1β and iNOS)^[1].

BuChE/FAAH-IN-1 (compound G15) (6.25-50 μM; pretreatment for 1 h + co-culture for 24 h) dose-dependently protects PC12 cells from H₂O₂-induced injury, increasing the survival rate from 39.8% to 57.1% in the 12.5-50 μM range^[1].

BuChE/FAAH-IN-1 (0.002-20 μM; 20 min) exhibits stronger inhibitory activity against eqBuChE than against eeAChE, with IC₅₀ values of 0.45 μM and 9.35 μM, respectively^[1].
BuChE/FAAH-IN-1 (0.01-200 μM; 60 min) exhibits moderate inhibitory activity against hAChE and stronger inhibitory activity against hBuChE, with IC₅₀ values of 16.84 μM and 2.44 μM, respectively^[1].
BuChE/FAAH-IN-1 is a time-dependent hFAAH inhibitor; after 60-minute preincubation, its IC₅₀ value decreases from 0.15 μM to 0.049 μM^[1].
BuChE/FAAH-IN-1 (20 μM; 15 min) exhibits weak inhibitory activity against hMAGL, with an inhibition rate of 23.8% at 20 μM^[1].
BuChE/FAAH-IN-1 (0.01-4 μM; 1-60 min) is a pseudo-irreversible hBuChE inhibitor with K_d = 0.38 μM^[1].
BuChE/FAAH-IN-1 (10 min) inhibits CES1 and CES2 with IC₅₀ values of 2.45 μM and 1.43 μM, respectively, and exhibits selectivity over hFAAH (SI of 14.4 and 8.38, respectively)^[1].
BuChE/FAAH-IN-1 (50 μM; 30 min) exhibits strong chelating ability toward Zn²⁺, moderate chelating effect on Fe³⁺, and weak interaction with other tested metal ions^[1].
BuChE/FAAH-IN-1 (25 μM; 24 h) exhibits good biocompatibility in HepG2, AML12, and PC12 cells, with cell viability above 80%^[1].
BuChE/FAAH-IN-1 (12.5-100 μM; pretreatment for 1 h + co-culture for 24 h) is well tolerated by BV2 cells at 12.5 μM, produces slight toxicity at 25 μM, and reverses LPS (HY-D1056)-induced microglial morphological activation at 25 μM^[1].